LTX-001 / Leal Therapeutics - LARVOL DELTA

Development of LTX-001, a Novel Oral Small Molecule for the Treatment of Schizophrenia (WFSBP 2025) - "In addition to treating positive symptoms of schizophrenia, modulation of the glutamatergic pathway has the potential to ameliorate negative and cognitive symptoms, while mitigating dopamine-related adverse effects. We have developed LTX-001, an investigational oral small molecule targeting glutaminase (GLS1), the rate-limiting enzyme for glutamate biosynthesis in the central nervous system (CNS), for the treatment of schizophrenia."

CNS Disorders • Psychiatry • Schizophrenia

Leal Therapeutics Announces $45 Million Financing to Progress Novel Therapies for Patients with Major Neurodegenerative and Neuropsychiatric Disorders (PRNewswire) - "The proceeds will be used to advance Leal's pipeline of antisense oligonucleotide (ASO) and small molecule therapeutics for patients with CNS disorders. Leal's lead programs are LTX-002, an ASO for patients with genetic or sporadic amyotrophic lateral sclerosis (ALS), and LTX-001, a small molecule for patients with schizophrenia. The company plans to submit Investigational New Drug (IND) applications for LTX-002 and LTX-001 by the end of 2024 and commence first-in-human clinical trials in early 2025."

Financing • IND • Amyotrophic Lateral Sclerosis • Schizophrenia